Stay updated on T-DXd in HER2 Expressing Tumors Clinical Trial

Sign up to get notified when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DXd in HER2 Expressing Tumors Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The Taiwan site entry has been updated from Taoyuan District, Taiwan, 333 to Taoyuan, Taiwan, 333. This change clarifies the city designation while preserving the postal code.
    Difference
    0.0%
    Check dated 2026-05-03T03:58:00.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The page’s footer “Revision” label has been updated from v3.5.2 to v3.5.3, indicating a site version update.
    Difference
    0.0%
    Check dated 2026-04-25T18:52:01.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Added Gurgaon, India, 122001 and Revision: v3.5.2. Deleted Gūrgaon, India, 122001 and Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-18T13:46:11.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    New dates (2026-04-08, 2026-04-09, 2027-03-23) were added and older dates (2026-03-26, 2026-03-27, 2027-07-30, 2026-03) were removed from the study record. These revisions update milestone timing and the record's update history for the trial.
    Difference
    0.2%
    Check dated 2026-04-11T10:39:45.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Enrollment updated to 477 participants across 89 locations; many site locations and contact details were removed.
    Difference
    5%
    Check dated 2026-03-28T03:44:29.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Added Gūrgaon, India and Naples, Italy as study locations and included a new publication citation (Oaknin A, Lee JY, Makker V, Oh DY, Banerjee S, Gonzalez-Martin A, Jung KH, Lugowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Puvvada S, Smith A, Meric-Bernstam F. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x. Epub 2024 Sep 11.) with Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-21T01:17:42.000Z thumbnail image

Stay in the know with updates to T-DXd in HER2 Expressing Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DXd in HER2 Expressing Tumors Clinical Trial page.